Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology

01-02-2020 | Primary Immunodeficiency | Original Article

Pulmonary Disease Burden in Primary Immune Deficiency Disorders: Data from USIDNET Registry

Authors: Meera Patrawala, Ying Cui, Limin Peng, Ramsay L. Fuleihan, Elizabeth K. Garabedian, Kiran Patel, Lokesh Guglani

Published in: Journal of Clinical Immunology | Issue 2/2020

Login to get access

Abstract

Purpose

Pulmonary manifestations are common in patients with primary immunodeficiency disorders (PIDs) but the prevalence, specific diseases, and their patterns are not well characterized.

Methods

We conducted a retrospective analysis of pulmonary diseases reported in the database of the United States Immunodeficiency Network (USIDNET), a program of the Immune Deficiency Foundation. PIDs were categorized into 10 groups and their demographics, pulmonary diagnoses and procedures, infections, prophylaxis regimens, and laboratory findings were analyzed.

Results

A total of 1937 patients with various PIDs (39.3% of total patients, 49.6% male, average age 37.9 years (SD = 22.4 years)) were noted to have a pulmonary disease comorbidity. Pulmonary diseases were categorized into broad categories: airway (86.8%), parenchymal (18.5%), pleural (4.6%), vascular (4.3%), and other (13.9%) disorders. Common variable immune deficiency (CVID) accounted for almost half of PIDs associated with airway, parenchymal, and other pulmonary disorders. Pulmonary procedures performed in 392 patients were mostly diagnostic (77.3%) or therapeutic (16.3%). These patients were receiving a wide variety of treatments, which included immunoglobulin replacement (82.1%), immunosuppressive (32.2%), anti-inflammatory (12.7%), biologic (9.3%), and cytokine (7.6%)-based therapies. Prophylactic therapy was being given with antibiotics (18.1%), antifungal (3.3%), and antiviral (2.2%) medications, and 7.1% of patients were on long-term oxygen therapy due to advanced lung disease.

Conclusions

Pulmonary manifestations are common in individuals with PID, but long-term pulmonary outcomes are not well known in this group of patients. Further longitudinal follow-up will help to define long-term prognosis of respiratory comorbidities and optimal treatment modalities.
Appendix
Available only for authorised users
Literature
1.
Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128.CrossRefPubMed
2.
Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRefPubMed
3.
Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221–30.CrossRefPubMed
4.
Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51(1):61–70.CrossRefPubMed
5.
Fernandez Perez ER, Hunter M, Katial RK. United States trends in mortality rates for primary immunodeficiency diseases. J Allergy Clin Immunol Pract. 2019;7(3):1045–8.CrossRefPubMed
6.
Yazdani R, Abolhassani H, Asgardoon M, Shaghaghi M, Modaresi M, Azizi G, et al. Infectious and noninfectious pulmonary complications in patients with primary immunodeficiency disorders. J Investig Allergol Clin Immunol. 2017;27(4):213–24.CrossRefPubMed
7.
El-Sayed ZA, Abramova I, Aldave JC, Al-Herz W, Bezrodnik L, Boukari R, et al. X-linked agammaglobulinemia (XLA):phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J. 2019;12(3):100018.CrossRefPubMedPubMedCentral
8.
Nonas S. Pulmonary manifestations of primary immunodeficiency disorders. Immunol Allergy Clin N Am. 2015;35(4):753–66.CrossRef
9.
Cinetto F, Scarpa R, Rattazzi M, Agostini C. The broad spectrum of lung diseases in primary antibody deficiencies. Eur Respir Rev. 2018;27(149).
10.
Baumann U, Routes JM, Soler-Palacín P, Jolles S. The lung in primary immunodeficiencies: new concepts in infection and inflammation. Front Immunol. 2018;9:1837.CrossRefPubMedPubMedCentral
11.
12.
Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med. 2015;3(8):651–60.CrossRefPubMed
13.
Jesenak M, Banovcin P, Jesenakova B, Babusikova E. Pulmonary manifestations of primary immunodeficiency disorders in children. Front Pediatr. 2014;2:77.CrossRefPubMedPubMedCentral
14.
Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650–7.CrossRefPubMedPubMedCentral
15.
Berger M, Geng B, Cameron DW, Murphy LM, Schulman ES. Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease. Respir Med. 2017;132:181–8.CrossRefPubMed
16.
Movahedi M, Aghamohammadi A, Farhoudi A, Moin M, Pourpak Z, Gharagozlou M, et al. Respiratory manifestations of chronic granulomatous disease; a clinical survey of patients from Iranian primary immunodeficiency registry. Iran J Allergy Asthma Immunol. 2003;2(1):45–51.PubMed
17.
Weinberger T, Fuleihan R, Cunningham-Rundles C, Maglione PJ. Factors beyond lack of antibody govern pulmonary complications in primary antibody deficiency. J Clin Immunol. 2019;39(4):440–7.CrossRefPubMedPubMedCentral
18.
Eden E, Choate R, Barker A, Addrizzo-Harris D, Aksamit TR, Daley CL, et al. The clinical features of bronchiectasis associated with alpha-1 antitrypsin deficiency, common variable immunodeficiency and primary ciliary dyskinesia--results from the U.S. bronchiectasis research registry. Chronic Obstr Pulm Dis. 2019;6(2):145–53.PubMedPubMedCentral
19.
Odnoletkova I, Kindle G, Quinti I, Grimbacher B, Knerr V, Gathmann B, et al. The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data. Orphanet J Rare Dis. 2018;13(1):201.CrossRefPubMedPubMedCentral
20.
Gathmann B, Mahlaoui N, Gérard L, Oksenhendler E, Warnatz K, Schulze I, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116–26.CrossRefPubMed
21.
Cereser L, De Carli M, d'Angelo P, Zanelli E, Zuiani C, Girometti R. High-resolution computed tomography findings in humoral primary immunodeficiencies and correlation with pulmonary function tests. World J Radiol. 2018;10(11):172–83.CrossRefPubMedPubMedCentral
22.
Salvator H, Mahlaoui N, Catherinot E, Rivaud E, Pilmis B, Borie R, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. Eur Respir J. 2015;45(6):1613–23.CrossRefPubMed
23.
Mahdaviani SA, Mohajerani SA, Rezaei N, Casanova JL, Mansouri SD, Velayati AA. Pulmonary manifestations of chronic granulomatous disease. Expert Rev Clin Immunol. 2013;9(2):153–60.CrossRefPubMed
24.
Costa-Carvalho BT, Wandalsen GF, Pulici G, Aranda CS, Sole D. Pulmonary complications in patients with antibody deficiency. Allergol Immunopathol (Madr). 2011;39(3):128–32.CrossRef
25.
Bagheri Y, Vosughi A, Azizi G, Yazdani R, Kiaee F, Hafezi N, et al. Comparison of clinical and immunological features and mortality in common variable immunodeficiency and agammaglobulinemia patients. Immunol Lett. 2019;210:55–62.CrossRefPubMed
26.
Tashtoush B, Memarpour R, Ramirez J, Bejarano P, Mehta J. Granulomatous-lymphocytic interstitial lung disease as the first manifestation of common variable immunodeficiency. Clin Respir J. 2018;12(1):337–43.CrossRefPubMed
27.
Tuijnenburg P, Lango Allen H, Burns SO, Greene D, Jansen MH, Staples E, et al. Loss-of-function nuclear factor kappaB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. J Allergy Clin Immunol. 2018;142(4):1285–96.CrossRefPubMedPubMedCentral
28.
Tuijnenburg P, Lango Allen H, de Bree GJ, Savic S, Jansen MH, Stockdale C, et al. Pathogenic NFKB2 variant in the ankyrin repeat domain (R635X) causes a variable antibody deficiency. Clin Immunol. 2019;203:23–7.CrossRefPubMed
29.
Aghamohammadi A, Allahverdi A, Abolhassani H, Moazzami K, Alizadeh H, Gharagozlou M, et al. Comparison of pulmonary diseases in common variable immunodeficiency and X-linked agammaglobulinaemia. Respirology. 2010;15(2):289–95.CrossRefPubMed
30.
Reisi M, Azizi G, Kiaee F, Masiha F, Shirzadi R, Momen T, et al. Evaluation of pulmonary complications in patients with primary immunodeficiency disorders. Eur Ann Allergy Clin Immunol. 2017;49(3):122–8.PubMed
31.
Stubbs A, Bangs C, Shillitoe B, Edgar JD, Burns SO, Thomas M, et al. Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy. Clin Exp Immunol. 2018;191(2):212–9.CrossRefPubMed
32.
Barnes S, Kotecha S, Douglass JA, Paul E, Hore-Lacy F, Hore-Lacey F, et al. Evolving practice: X-linked agammaglobulinemia and lung transplantation. Am J Transplant. 2015;15(4):1110–3.CrossRefPubMed
33.
Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, et al. Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med. 1999;340(9):692–702.CrossRefPubMed
34.
35.
Kawai T, Watanabe N, Yokoyama M, Nakazawa Y, Goto F, Uchiyama T, et al. Interstitial lung disease with multiple microgranulomas in chronic granulomatous disease. J Clin Immunol. 2014;34(8):933–40.CrossRefPubMed
36.
Pogrebniak HW, Gallin JI, Malech HL, Baker AR, Moskaluk CA, Travis WD, et al. Surgical management of pulmonary infections in chronic granulomatous disease of childhood. Ann Thorac Surg. 1993;55(4):844–9.CrossRefPubMed
37.
Efrati O, Gonik U, Bielorai B, Modan-Moses D, Neumann Y, Szeinberg A, et al. Fiberoptic bronchoscopy and bronchoalveolar lavage for the evaluation of pulmonary disease in children with primary immunodeficiency and cancer. Pediatr Blood Cancer. 2007;48(3):324–9.CrossRefPubMed
38.
Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210–2.CrossRefPubMed
39.
Notarangelo LD, Plebani A, Mazzolari E, Soresina A, Bondioni MP. Genetic causes of bronchiectasis: primary immune deficiencies and the lung. Respiration. 2007;74(3):264–75.CrossRefPubMed
40.
de Gracia J, Vendrell M, Alvarez A, Pallisa E, Rodrigo MJ, de la Rosa D, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol. 2004;4(6):745–53.CrossRefPubMed
41.
Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21–30.CrossRefPubMed
42.
Chen Y, Stirling RG, Paul E, Hore-Lacy F, Thompson BR, Douglass JA. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immunol. 2011;127(6):1414–7.CrossRefPubMed
43.
Soler-Palacin P, de Gracia J, Gonzalez-Granado LI, Martin C, Rodriguez-Gallego C, Sanchez-Ramon S, et al. Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management. Respir Res. 2018;19(1):219.CrossRefPubMedPubMedCentral
44.
Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, et al. British Lung Foundation/United Kingdom primary immunodeficiency network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2017;5(4):938–45.CrossRefPubMed
45.
Jolles S, Sánchez-Ramón S, Quinti I, Soler-Palacín P, Agostini C, Florkin B, et al. Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clin Exp Immunol. 2017;190(2):226–34.CrossRefPubMedPubMedCentral
Metadata
Title
Pulmonary Disease Burden in Primary Immune Deficiency Disorders: Data from USIDNET Registry
Authors
Meera Patrawala
Ying Cui
Limin Peng
Ramsay L. Fuleihan
Elizabeth K. Garabedian
Kiran Patel
Lokesh Guglani
Publication date
01-02-2020
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 2/2020
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-019-00738-w
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits